What does this research mean for the field?

In patients with inflammatory bowel disease, tirzepatide reduces the risk of intravenous steroid use and composite adverse clinical outcomes compared to GLP-1 receptor agonists, with a similar safety profile. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare clinical outcomes and safety profiles in patients with inflammatory bowel disease treated with tirzepatide versus glucagon-like peptide-1 receptor agonists.

September 12, 2026Intestinal ResearchOpen Access

Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study

View Full Paper

Ask AI

Bookmark

Authors

KPKrishan S. Patel BFButros Fakhoury KPKavin Parmar

Discussion

Member takes

Overview

Retrospective matched cohort study finds lower intravenous steroid risk with tirzepatide versus GLP-1 receptor agonists in inflammatory bowel disease, indicating dual incretin agonism benefits.

Key Points

To compare clinical outcomes and safety profiles in patients with inflammatory bowel disease treated with tirzepatide versus glucagon-like peptide-1 receptor agonists.
Conducted a retrospective 1:1 propensity score-matched cohort study using a multi-institutional U.S. database of adult patients with inflammatory bowel disease prescribed tirzepatide or GLP-1 receptor agonists between May 2022 and January 2025 (N=3,042 per cohort; mean age, 54.6 years; 71.3% female).
Evaluated 18-month outcomes including intravenous steroid use, intestinal surgery, hospitalizations, emergency department visits, and adverse outcomes over a median follow-up of 540 days.
Tirzepatide was associated with a significantly decreased risk of intravenous steroid use (aHR, 0.81; 95% CI, 0.68–0.94) and composite IBD outcomes (aHR, 0.86; 95% CI, 0.73–0.97) compared with GLP-1 receptor agonists.
Among patients with ulcerative colitis, tirzepatide similarly demonstrated a reduced risk of intravenous steroid administration (aHR, 0.82; 95% CI, 0.69–0.97).
Risks of intestinal surgery, hospitalizations, emergency department visits, and overall adverse outcomes did not differ significantly between cohorts.

Cite This Study

Patel et al. (2026) studied this question.

synapsesocial.com/papers/6aa5542f327956e4761fa048 https://doi.org/10.5217/ir.2026.00152

View Full Paper

Ask AI

Bookmark

September 12, 2026Intestinal ResearchOpen Access

Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study

View Full Paper

Ask AI

Bookmark

Authors

KPKrishan S. Patel BFButros Fakhoury KPKavin Parmar

Discussion

Member takes

Overview

Retrospective matched cohort study finds lower intravenous steroid risk with tirzepatide versus GLP-1 receptor agonists in inflammatory bowel disease, indicating dual incretin agonism benefits.

Key Points

To compare clinical outcomes and safety profiles in patients with inflammatory bowel disease treated with tirzepatide versus glucagon-like peptide-1 receptor agonists.
Conducted a retrospective 1:1 propensity score-matched cohort study using a multi-institutional U.S. database of adult patients with inflammatory bowel disease prescribed tirzepatide or GLP-1 receptor agonists between May 2022 and January 2025 (N=3,042 per cohort; mean age, 54.6 years; 71.3% female).
Evaluated 18-month outcomes including intravenous steroid use, intestinal surgery, hospitalizations, emergency department visits, and adverse outcomes over a median follow-up of 540 days.
Tirzepatide was associated with a significantly decreased risk of intravenous steroid use (aHR, 0.81; 95% CI, 0.68–0.94) and composite IBD outcomes (aHR, 0.86; 95% CI, 0.73–0.97) compared with GLP-1 receptor agonists.
Among patients with ulcerative colitis, tirzepatide similarly demonstrated a reduced risk of intravenous steroid administration (aHR, 0.82; 95% CI, 0.69–0.97).
Risks of intestinal surgery, hospitalizations, emergency department visits, and overall adverse outcomes did not differ significantly between cohorts.

Cite This Study

Patel et al. (2026) studied this question.

synapsesocial.com/papers/6aa5542f327956e4761fa048 https://doi.org/10.5217/ir.2026.00152

View Full Paper

Ask AI

Bookmark